These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35380392)

  • 1. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
    Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
    Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
    Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
    Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
    Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis.
    Mälkönen T; Nuutinen P; Hallinen T; Soini E; Nissinen R; Wennerstöm C; Rantanen T; Hagman JH; Harvima R; Höök-Nikanne J; Ilves T; Lintu P; Malanin K; Soramäki I; Tasanen K; Teho A; Vähävihu K; Itälinna S; Leinonen P; Sarajärvi P; Huilaja L; Pasternack R
    Acta Derm Venereol; 2022 Jan; 102():adv00631. PubMed ID: 34904684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study - IL PSO (ITALIAN LANDSCAPE PSORIASIS).
    Gargiulo L; Ibba L; Malagoli P; Angileri RG; Bardazzi F; Bernardini N; Burlando M; Carrera CG; Chiricozzi A; Dapavo P; Dini V; Fabbrocini G; Gaiani FM; Galluzzo M; Giofré C; Guarneri C; Loconsole F; Malara G; Marcelli L; Megna M; Piaserico S; Talamonti M; Costanzo A; Narcisi A
    J Eur Acad Dermatol Venereol; 2023 May; 37(5):1017-1027. PubMed ID: 36695061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
    Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
    Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life experience of guselkumab in patients with psoriasis.
    Snast I; Sherman S; Holzman R; Hodak E; Pavlovsky L
    Dermatol Ther; 2020 Nov; 33(6):e13964. PubMed ID: 32618384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
    Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
    J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study.
    Gargiulo L; Ibba L; Cortese A; Toso F; Vignoli CA; Fiorillo G; Piscazzi F; Valenti M; Costanzo A; Narcisi A
    J Drugs Dermatol; 2024 Aug; 23(8):632-639. PubMed ID: 39093650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Chinchay FV; Galán-Gutiérrez M
    Dermatol Ther; 2022 Oct; 35(10):e15760. PubMed ID: 35971573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
    Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
    Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of short-term (16-week) effectiveness and safety of guselkumab in patients with psoriasis: A prospective real-life study on the Chinese population.
    Zhuang JY; Li JS; Zhong YQ; Zhang FF; Li XZ; Su H; Zhang ZQ; Wang XH; Chen YF
    Dermatol Ther; 2021 Sep; 34(5):e15054. PubMed ID: 34228392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.
    Bardazzi F; Viviani F; Merli Y; Di Lernia V; Peccerillo F; Conti A; Lasagni C; Tabanelli M; D'Adamio S; Di Nuzzo S; Cortellazzi C; Filippi F
    Expert Opin Biol Ther; 2022 Dec; 22(12):1561-1566. PubMed ID: 35388713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
    Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis.
    Marletta D; Murgia G; Cattaneo A; Carrera C; Marzano A
    J Drugs Dermatol; 2022 Aug; 21(8):864-866. PubMed ID: 35946964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study.
    Puig L; Daudén E; Cuervas-Mons M; Novella C; Guisado C
    J Eur Acad Dermatol Venereol; 2023 Aug; ():. PubMed ID: 37567861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
    Galluzzo M; Marcelli L; Vellucci L; Paganini C; Maffei V; Tofani L; Belcastro A; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2023 Apr; 23(4):371-381. PubMed ID: 36971507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life data over 36 weeks of guselkumab treatment in psoriasis patients: A single-center study from Turkey.
    Solak EÖ; Aba FC; Çınar SL; Kartal D; Borlu M
    J Cosmet Dermatol; 2024 May; 23(5):1912-1917. PubMed ID: 38491736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.